Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study
在 3 期遗传性血管性水肿预防试验中评估口服激肽释放酶抑制剂 avoralstat:OPuS-2 研究
期刊:Allergy
影响因子:12
doi:10.1111/all.13466
Riedl, M A; Aygören-Pürsün, E; Baker, J; Farkas, H; Anderson, J; Bernstein, J A; Bouillet, L; Busse, P; Manning, M; Magerl, M; Gompels, M; Huissoon, A P; Longhurst, H; Lumry, W; Ritchie, B; Shapiro, R; Soteres, D; Banerji, A; Cancian, M; Johnston, D T; Craig, T J; Launay, D; Li, H H; Liebhaber, M; Nickel, T; Offenberger, J; Rae, W; Schrijvers, R; Triggiani, M; Wedner, H J; Dobo, S; Cornpropst, M; Clemons, D; Fang, L; Collis, P; Sheridan, W P; Maurer, M